Pharma’s Aim: Tap Innovation In Emerging Markets To Fix Woes At Home (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Pharma must learn how to apply the best of its experiences in emerging markets to its traditional business, or, experts warn, invigorated competition from more nimble, faster-growing local players that have enjoyed success on their own turf will become a global threat.
You may also be interested in...
New Approaches To Innovation Needed To Reach Globe's Poor At The "Bottom Of The Pyramid" - And To Fend Off Emerging Competitors Around The World
CAMBRIDGE, Mass. - Life science companies looking to provide healthcare solutions to the poorer, "bottom of the pyramid" - a population reaching more than 600 million people in India alone - should focus on business model innovation as much as on innovative products, according to delegates at the U.S.-India Chamber of Commerce biopharmaceutical and healthcare summit in Cambridge, Mass
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Building Long-Term Value Into Near-Term Commercial Strategy
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.